Literature DB >> 20378577

Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.

Christopher J Stasik1, Hiroaki Nitta, Wenjun Zhang, Charles H Mosher, James R Cook, Raymond R Tubbs, Joseph M Unger, Tracy A Brooks, Daniel O Persky, Sarah T Wilkinson, Thomas M Grogan, Lisa M Rimsza.   

Abstract

BACKGROUND: Translocations involving the MYC gene and increased MYC mRNA levels are associated with poor outcome in diffuse large B-cell lymphoma. However, the presence of increased MYC gene copy number and/or polysomy of chromosome 8 have not been previously described. DESIGN AND METHODS: Utilizing dual color chromogenic in situ hybridization, we investigated MYC gene copy and chromosome 8 centromere numbers in 52 cases of diffuse large B-cell lymphoma. Cases were divided into those with "increased" or "not increased" MYC gene copy number for comparison with MYC mRNA levels, Ki-67 values, and survival.
RESULTS: Increased MYC gene copy number was present in 38% of cases. Overall, the average MYC mRNA level was 2398 (range, 342 - 9783) and the percentage of nuclei positive for Ki-67 was 57.5% (range, 20-87%). Within the group with increased MYC copy number, the MYC mRNA values ranged from 816 to 5912 (average, 2843) and the Ki-67 values ranged from 23% to 83% (average, 57%). Within the group with not increased MYC copy number, MYC mRNA values ranged from 342 to 9783 (average, 2118) and the Ki-67 values ranged from 20% to 87% (average, 58%). There was a statistically significant relationship between increased MYC gene copy number and increased MYC mRNA (P=0.034) and a trend toward a relationship between increased mRNA and higher Ki-67 values.
CONCLUSIONS: This is the first report that low level copy number increases are common in diffuse large B-cell lymphoma and that these changes correlate with MYC mRNA in a statistically significant manner. MYC copy number changes are an additional possible molecular mechanism that may result in increased mRNA and, likely, high proliferation and poor outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378577      PMCID: PMC2857189          DOI: 10.3324/haematol.2009.012864

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  38 in total

1.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Authors:  Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

2.  A far upstream element stimulates c-myc expression in undifferentiated leukemia cells.

Authors:  M I Avigan; B Strober; D Levens
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

3.  Quadruplex-duplex competition in the nuclease hypersensitive element of human c-myc promoter: C to T mutation in C-rich strand enhances duplex association.

Authors:  Kangkan Halder; Vidhi Mathur; Dipankar Chugh; Anjali Verma; Shantanu Chowdhury
Journal:  Biochem Biophys Res Commun       Date:  2005-02-04       Impact factor: 3.575

4.  DNA tetraplex formation in the control region of c-myc.

Authors:  T Simonsson; P Pecinka; M Kubista
Journal:  Nucleic Acids Res       Date:  1998-03-01       Impact factor: 16.971

5.  Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial.

Authors:  T P Miller; T M Grogan; S Dahlberg; C M Spier; R M Braziel; P M Banks; K Foucar; C R Kjeldsberg; N Levy; B N Nathwani
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

6.  c-Myc-regulated microRNAs modulate E2F1 expression.

Authors:  Kathryn A O'Donnell; Erik A Wentzel; Karen I Zeller; Chi V Dang; Joshua T Mendell
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Authors:  Cheng Li; Sang-Woo Kim; Deepak Rai; Aswani R Bolla; Siddharth Adhvaryu; Marsha C Kinney; Ryan S Robetorye; Ricardo C T Aguiar
Journal:  Blood       Date:  2009-03-10       Impact factor: 22.113

8.  A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif.

Authors:  R Duncan; L Bazar; G Michelotti; T Tomonaga; H Krutzsch; M Avigan; D Levens
Journal:  Genes Dev       Date:  1994-02-15       Impact factor: 11.361

9.  Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma.

Authors:  Robin A Roberts; Constantine M Sabalos; Michael L LeBlanc; Ralph R Martel; Yvette M Frutiger; Joseph M Unger; Ihab W Botros; Matthew P Rounseville; Bruce E Seligmann; Thomas P Miller; Thomas M Grogan; Lisa M Rimsza
Journal:  Lab Invest       Date:  2007-08-13       Impact factor: 5.662

10.  The functional response of upstream DNA to dynamic supercoiling in vivo.

Authors:  Fedor Kouzine; Suzanne Sanford; Zichrini Elisha-Feil; David Levens
Journal:  Nat Struct Mol Biol       Date:  2008-01-13       Impact factor: 15.369

View more
  29 in total

1.  Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.

Authors:  Andrés E Quesada; L Jeffrey Medeiros; Parth A Desai; Pei Lin; Jason R Westin; Huda M Hawsawi; Peng Wei; Guilin Tang; Adam C Seegmiller; Nishitha M Reddy; C Cameron Yin; Wei Wang; Jie Xu; Roberto N Miranda; Zhuang Zuo; Shaoying Li
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  Biology of double-hit B-cell lymphomas.

Authors:  R Coleman Lindsley; Ann S LaCasce
Journal:  Curr Opin Hematol       Date:  2012-07       Impact factor: 3.284

3.  FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.

Authors:  Rizwan Saffie; Nan Zhou; Delphine Rolland; Özlem Önder; Venkatesha Basrur; Sydney Campbell; Kathryn E Wellen; Kojo S J Elenitoba-Johnson; Brian C Capell; Luca Busino
Journal:  Cancer Res       Date:  2020-04-29       Impact factor: 12.701

4.  Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas.

Authors:  Rachael Thomas; Eric L Seiser; Alison Motsinger-Reif; Luke Borst; Victor E Valli; Kathryn Kelley; Steven E Suter; David Argyle; Kristine Burgess; Jerold Bell; Kerstin Lindblad-Toh; Jaime F Modiano; Matthew Breen
Journal:  Leuk Lymphoma       Date:  2011-03-07

Review 5.  The clinicopathologic spectrum of mature aggressive B cell lymphomas.

Authors:  Lisa Rimsza; Stefania Pittaluga; Stephan Dirnhofer; Christiane Copie-Bergman; Laurence de Leval; Fabio Facchetti; Stefano Pileri; Andreas Rosenwald; Andrew Wotherspoon; Falko Fend
Journal:  Virchows Arch       Date:  2017-08-26       Impact factor: 4.064

6.  BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma.

Authors:  Samantha L Kendrick; Lucas Redd; Andrea Muranyi; Leigh A Henricksen; Stacey Stanislaw; Lynette M Smith; Anamarija M Perry; Kai Fu; Dennis D Weisenburger; Andreas Rosenwald; German Ott; Randy D Gascoyne; Elaine S Jaffe; Elías Campo; Jan Delabie; Rita M Braziel; James R Cook; Raymond R Tubbs; Louis M Staudt; Wing Chung Chan; Christian Steidl; Thomas M Grogan; Lisa M Rimsza
Journal:  Hum Pathol       Date:  2014-06-26       Impact factor: 3.466

7.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Authors:  Daniel J Landsburg; Marissa K Falkiewicz; Adam M Petrich; Benjamin A Chu; Amir Behdad; Shaoying Li; L Jeffrey Medeiros; Ryan D Cassaday; Nishitha M Reddy; Martin A Bast; Julie M Vose; Kimberly R Kruczek; Scott E Smith; Priyank Patel; Francisco Hernandez-Ilizaliturri; Reem Karmali; Saurabh Rajguru; David T Yang; Joseph J Maly; Kristie A Blum; Weiqiang Zhao; Charles Vanslambrouck; Chadi Nabhan
Journal:  Br J Haematol       Date:  2016-07-29       Impact factor: 6.998

8.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

9.  Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma.

Authors:  Carlo Valentino; Samantha Kendrick; Nathalie Johnson; Randy Gascoyne; Wing C Chan; Dennis Weisenburger; Rita Braziel; James R Cook; Raymond Tubbs; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Elaine Jaffe; Wenjun Zhang; Patrick Brunhoeber; Hiro Nitta; Tom Grogan; Lisa Rimsza
Journal:  Am J Clin Pathol       Date:  2013-02       Impact factor: 2.493

Review 10.  MYC oncogene in myeloid neoplasias.

Authors:  M Dolores Delgado; Marta Albajar; M Teresa Gomez-Casares; Ana Batlle; Javier León
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.